Despite these challenges, agents such as tebentafusp (CD3 x gp100) and tarlatamab (CD3 x DLL3) have been approved for uveal melanoma15 and small cell lung cancer,16 respectively. Here, DLL3 is linked to small cell lung carcinoma.